Your browser doesn't support javascript.
loading
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Choueiri, Toni K; Larkin, James; Oya, Mototsugu; Thistlethwaite, Fiona; Martignoni, Marcella; Nathan, Paul; Powles, Thomas; McDermott, David; Robbins, Paul B; Chism, David D; Cho, Daniel; Atkins, Michael B; Gordon, Michael S; Gupta, Sumati; Uemura, Hirotsugu; Tomita, Yoshihiko; Compagnoni, Anna; Fowst, Camilla; di Pietro, Alessandra; Rini, Brian I.
Affiliation
  • Choueiri TK; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu.
  • Larkin J; Royal Marsden NHS Foundation Trust, London, UK.
  • Oya M; Keio University Hospital, Tokyo, Japan.
  • Thistlethwaite F; Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; Faculty of Biology, Medicine and Health, University of Manchester Manchester, UK.
  • Martignoni M; Pfizer, Milan, Italy.
  • Nathan P; Mount Vernon Cancer Centre, Northwood, UK.
  • Powles T; Royal Free Hospital, London, UK.
  • McDermott D; Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Robbins PB; Pfizer, San Diego, CA, USA.
  • Chism DD; Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Cho D; NYU Medical Oncology Associates, New York, NY, USA.
  • Atkins MB; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
  • Gordon MS; HonorHealth Research Institute, Scottsdale, AZ, USA.
  • Gupta S; Huntsman Cancer Hospital, Salt Lake City, UT, USA.
  • Uemura H; Kindai University Hospital, Osaka, Japan.
  • Tomita Y; Department of Urology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
  • Compagnoni A; Pfizer, Milan, Italy.
  • Fowst C; Pfizer, Milan, Italy.
  • di Pietro A; Pfizer, Milan, Italy.
  • Rini BI; Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Lerner College of Medicine, Cleveland, OH, USA.
Lancet Oncol ; 19(4): 451-460, 2018 04.
Article in En | MEDLINE | ID: mdl-29530667
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Antineoplastic Combined Chemotherapy Protocols / Kidney Neoplasms Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Antineoplastic Combined Chemotherapy Protocols / Kidney Neoplasms Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2018 Type: Article